Natera Stock Jumps on Cancer Test Trial

Natera stock jumps as its Signatera cancer test is chosen for a major bladder cancer clinical trial across the US and Canada, aiming to optimize radiation therapy. This follows strong second-quarter results and a history of Signatera predicting immunotherapy success, fueling investor optimism despite market fluctuations. With shares near their yearly high and the genetic testing sector booming, Natera's advancements are attracting significant attention. Hosted on Acast. See acast.com/privacy for more information.